Results 91 to 100 of about 36,737 (275)
The Journal of Physiology, EarlyView.Abstract figure legend Schematic illustration of the bidirectional causative link between cerebral amyloid‐beta (Aβ) angiopathy and cardiovascular disease in Alzheimer's disease (AD). Common cardiovascular risk factors like microvascular thrombosis, diabetes, atrial fibrillation, hypertension and atherosclerosis lead to cerebral hypoperfusion and ...
Samuel Parker +2 more
wiley +1 more source
Biomarker Research, 2023 Light chain amyloidosis (AL) is a rare disease caused by the generalized deposition of misfolded free light chains. Patients with immunoglobulin M gammopathy (IgM) and indolent B-cell lymphoma such as marginal zone lymphoma (MZL) may in some instances ...
Felix Korell +8 more
doaj +1 more source
European Journal of Haematology, Volume 116, Issue 3, Page 226-234, March 2026.ABSTRACT Response assessment during treatment of multiple myeloma (MM) typically relies on immunofixation and serum electrophoresis. However, low levels of IgG and especially IgA paraprotein are difficult to quantify reliably. The Hevylite Assay quantifies the kappa and lambda fractions of IgG and IgA separately and is useful to determine response to ...
Tim Richardson +125 more
wiley +1 more source
Classic features of primary systemic amyloidosis (AL amyloidosis) leading to diagnosis of plasma cell myeloma [PDF]
, 2019 The diagnosis of primary systemic amyloidosis, also known as AL (amyloid light-chain) amyloidosis, is often delayed owing to its nonspecific manifestations as well as its rarity.
Behrens, Emily +3 more
core
Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis [PDF]
, 2016 Search strategy.
Lei Zhao, Quan Fang, Zhuang Tian
core +2 more sources
European Journal of Haematology, Volume 116, Issue 3, Page 256-266, March 2026.ABSTRACT Introduction Following treatment, relapse of Multiple Myeloma (MM) occurs due to measurable residual disease (MRD). As therapeutic options expand, advances in response assessment become more critical, necessitating more sensitive MRD detection methods.
Aisling O'Brien +2 more
wiley +1 more source
Echocardiographic phenotype for refined risk stratification and treatment selection in light chain amyloidosis with heart failure [PDF]
, 2023 Hong Yang +8 more
openalex +1 more source
Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry
Swiss Medical WeeklyAIMS OF THE STUDY: Systemic amyloidoses are rare protein-folding diseases with heterogeneous, often nonspecific clinical presentations. To better understand systemic amyloidoses and to apply state-of-the-art diagnostic pathways and treatment, the ...
Sofie Brouwers +17 more
doaj +1 more source
Journal of the Peripheral Nervous System, Volume 31, Issue 1, March 2026.ABSTRACT Background and Aims In individuals with hereditary transthyretin amyloidosis (ATTRv) polyneuropathy, monitoring of disease progression and treatment response is crucial. The objective is to determine if serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) are reliable biomarkers of ATTRv polyneuropathy ...
Valentin Loser +9 more
wiley +1 more source
Blood Advances, 2018 : We evaluated the impact of light chain type, lambda (λ) or kappa (κ), on disease features and outcomes in patients with immunoglobulin light chain (AL) amyloidosis receiving stem cell transplant at the Mayo Clinic between October 2002 and August 2016 ...
M Hasib Sidiqi +14 more
doaj +1 more source